Sanofi buys back US orthopaedic rights to Hyalgan
This article was originally published in Clinica
Executive Summary
Sanofi-Synthelabo's US subsidiary is to buy back OrthoLogic's US distribution rights to market the synovial fluid substitute Hyalgan to those suffering knee pain through osteoarthritis.